<DOC>
	<DOCNO>NCT01972841</DOCNO>
	<brief_summary>The purpose study examine well two medicine ( solifenacin succinate mirabegron ) combine work compare medicine alone treatment bladder problem .</brief_summary>
	<brief_title>This Multinational Study Comparing Efficacy Safety Two Medicines , Solifenacin Succinate Mirabegron Taken Together , Separately , Mock Treatment ( Placebo ) Subjects With Symptoms Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Urinary Bladder Diseases</mesh_term>
	<mesh_term>Urologic Diseases</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subject willing able complete micturition diary questionnaire correctly able measure his/her vital sign home stipulate time point , use device provide study personnel , adequately record reading ; Subject symptoms `` wet '' OAB ( urinary frequency urgency incontinence ) least 3 month ; Subject significant PVR volume ( &gt; 150 mL ) ; Subject neurological cause detrusor overactivity ( e.g . neurogenic bladder , diabetic neuropathy autonomic component bladder involvement , systemic central neurological disease multiple sclerosis Parkinson 's disease autonomic component bladder involvement ) . An autonomic component infer autonomic function affect , include heart rate , blood pressure , perspiration digestion . Subject indwell catheter practice intermittent self catheterization . Subject chronic inflammation bladder pain syndrome /interstitial cystitis , symptomatic bladder stone previous current radiation cystitis . Subject receive intravesical treatment past 12 month e.g. , botulinum toxin , resiniferatoxin , capsaicin . Subject moderate severe hepatic impairment Subject severe renal impairment Subject clinically significant abnormal ECG Subject concurrent malignancy history cancer ( except noninvasive skin cancer ) within last 5 year prior screen . Subject average QTcF interval &gt; 450 m male &gt; 470 m female base triplicate ECGs complete Screening risk QT prolongation ( e.g. , family history long QT syndrome , hypokalaemia ) . Subject severe hypertension , define sit average systolic blood pressure ≥ 180 mmHg and/or average diastolic blood pressure ≥ 110 mmHg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Combination Therapy</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary Incontinence</keyword>
	<keyword>Nocturia</keyword>
	<keyword>Solifenacin Succinate</keyword>
</DOC>